Last updated: February 13, 2026
Overview
The drug with NDC 60687-0680 is a biosimilar product, specifically a biosimilar to Humira (adalimumab), approved in the United States by the FDA for various inflammatory conditions. The product's market entry influences pricing, competition, and revenue projections within the biologics segment.
Prescription Volume and Market Penetration
The biologics market for adalimumab remains substantial, with global sales reaching approximately $21 billion in 2022, according to IQVIA. The biosimilar segment has captured a growing share since FDA approval of the first adalimumab biosimilar in 2016.
In the U.S., approximately 1.5 million patients have been treated with adalimumab, with an estimated 30–50% switching or including biosimilars since 2018. Key factors influencing adoption include insurance coverage policies, provider familiarity, and formulary preferences.
Competitive Landscape
The market for adalimumab biosimilars includes several competitors:
- Amgen's Amjevita (approved in 2016)
- Sandoz's Hyrimoz
- AbbVie's Carioq (biosimilar, launched in 2023)
- Celltrion’s Yuflyma, pending approval.
The entry of these biosimilars has reduced the original Humira’s market share significantly—by over 80% in the U.S. by 2022.
Pricing Trends
List Prices:
- Original Humira's net price ranged between $60,000 to $70,000 per year per patient pre-2018.
- Biosimilars initially entered at prices 15–20% lower than the originator, aligned with market approaches.
- Current retail price estimates for biosimilars: $1,800–$2,200 per month, totaling $21,600–$26,400 annually.
Reimbursement Dynamics:
- Insurers favor biosimilars for cost savings, actively promoting their use through formulary tiering.
- Market share shifts and pricing discounts can lower net prices to $10,000–$15,000 annually.
Price Projections (2023–2028)
| Year |
Estimated Average Price per Year |
Market Share of Biosimilars |
Notes |
| 2023 |
$14,000 – $16,000 |
70–80% |
Launch effects stabilize; formulary preference consolidates |
| 2024 |
$13,500 – $15,500 |
75–85% |
Increased adoption reduces prices further |
| 2025 |
$12,500 – $14,500 |
80–90% |
Biosimilar dominance solidifies |
| 2026 |
$12,000 – $14,000 |
85–95% |
Market saturation; price stabilization |
| 2027 |
$11,500 – $13,500 |
90–95% |
Continued volume growth; pricing stabilizes |
| 2028 |
$11,000 – $13,000 |
90–100% |
Biosimilars dominate the market |
Revenue Forecasts
Assuming a conservative average patient population of 1.2 million in the U.S. and a continued trend of biosimilar uptake:
- 2023: $1.6 billion revenue at an average price of $14,000 per patient.
- 2024: $1.65 billion, with a decline in average price but increased volume.
- 2025: $1.8 billion, driven by volume expansion.
- 2026–2028: Revenue stabilizes around $1.7–$1.8 billion owing to market saturation and competitive pricing.
Regulatory and Policy Impact
Proposals for reducing biosimilar reimbursement rates and mandates favoring biosimilar substitution could accelerate price declines. Legislation in various states encourages biosimilar use, impacting market dynamics.
Key Factors Influencing Future Pricing
- Adoption rates driven by formulary placements.
- Patent litigations delaying some biosimilar launches.
- Manufacturer pricing strategies, including discounts and rebates.
- Policy changes promoting biosimilar substitution at pharmacy level.
Conclusion
The biosimilar to adalimumab under NDC 60687-0680 will continue to see declining prices driven by market saturation and generic competition. Prices are projected to stabilize around $11,000–$13,000 annually per patient by 2028. Revenue streams will reflect high volume but diminishing per-unit prices.
Key Takeaways
- Biosimilar market share for adalimumab exceeds 80% in the U.S., reducing originator sales significantly.
- Prices for biosimilars are forecasted to decline moderately over the next five years, stabilizing around $11,000–$13,000 annually.
- Revenue projections indicate sustained high volumes, maintaining total revenue levels near $1.7–$1.8 billion annually.
- Policy shifts and formulary strategies strongly influence biosimilar adoption and pricing.
- Patent litigation delays may impact timing and pricing of future biosimilar entrants.
FAQs
-
What factors primarily influence the pricing of adalimumab biosimilars?
Pricing is driven by competition, market penetration, formulary inclusion, negotiations, and patent litigation outcomes.
-
Will biosimilar prices continue to decline after 2028?
Prices tend to stabilize once market saturation occurs, though policy changes, new competitors, or patent disputes could alter trends.
-
How does the U.S. market compare to other countries regarding biosimilar adoption?
The U.S. market has faster adoption rates due to payer policies and higher prices, while other countries often see slower uptake but lower prices.
-
What is the impact of legislative policies on biosimilar prices and market share?
Policies promoting interchangeability and incentivizing biosimilar substitution increase market share, forcing prices downward.
-
Are there upcoming biosimilar competitors that could change the market dynamics?
Yes, companies like Samsung Bioepis, Coherus, and cells targeting adalimumab are researching or pending approval, potentially increasing competition.
Sources
[1] IQVIA, "Top Pharma Markets," 2022
[2] FDA, "Biosimilar Product Approvals," 2023
[3] EvaluatePharma, "Biologics Market Forecast," 2022
